))
S4 Ep 1 | Bringing new Perspective to Structured based Drug Design
Manage episode 355247758 series 2933391
Innhold levert av SciPro. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av SciPro eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
A special series of Life Sci AI: The Podcast Series looking at AI in Drug Discovery begins with a fascinating episode featuring Dr David Wright, CTO and Co-Founder of Kuano. The discussion delved deep into the revolutionary role Kauno is playing in the Drug Discovery process.
Dr David Wright is the CTO and Co-Founder of Kuano, a startup whose mission is to use a unique combination of simulation and AI to bring quantum detail to drug design. By starting from an exquisitely detailed picture of enzyme mechanisms they are looking to create a new generation of therapeutics, whose current projects include creating novel anti-bowel cancer drugs.
Before co-founding Kuano, Dr Wright used simulation to understand how atomic details impact drug binding at UCL. His journey to Kuano involved collaborating in large international collaborative projects (CompbioMed, CCP-SAS, CHAIN, INSPIRE) that brought together experts from the supercomputing, academic and pharmaceuticals world to advance drug design. His multidisciplinary outlook is reflected in how Kuano is bringing a new perspective to structure-based drug design.
To speak to Nick, please drop an email to n.mahoney@sciproglobal.com
33 episoder
Del
